December 03-04, 2018
Madrid, Spain
PULSUS brings in a new spin on conferences by presenting the latest scientific improvements in your field. Listen to motivating keynotes from thought leaders, or rub elbows with pioneers across the globe. Madrid is all set for an amazing event as PULSUS proudly presents the “International Conference on Alzheimers, Dementia and Related Neurodegenerative Diseases” slated on December 03-04, 2018 at Madrid, Spain. The theme of the conference is “Leading Advancements and Remedies in the Neurodegenerative Disorders”.
Neurology focusses on the diagnosis and treatment of diseases affecting the nervous system. The nervous system includes brain and Spinal cord. Neurodegenerative Disorders occurs when the neurons in the human brain are affected. Neurodegeneration is the process of loss of structure or function of neurons, it may also include death of neurons. Neurodegeneration leads to many diseases like Myotrophic lateral sclerosis, Huntington's , Parkinson's and Alzheimer's. The most common type are Parkinson's disease and Alzheimer's disease.
Pulsus Group
Pulsus Group is a Medical publisher that adheres to stringent peer-review procedure with a view to set an example in promoting standard medical research with integrity. Pulsus Group takes pride in getting the endorsements of prestigious associations and societies like Germany medical societies. As an ardent supporter of medical publishing, Pulsus Group closely associates with the Germany and other international medical research associations. It publishes a wide range of medical journals that focus on medical specialties like Neurology, Cardiology, Pscyhiatry, Surgery, Dental Health, Physics and Reproductive Medicine.
Pulsus Group is an internationally renowned peer-review publisher in scientific, technical, and medical journals established in the year 1984 with offices in Ontario, Canada and Hyderabad. India has acquired Andrew John Publishing and openaccessjournals.com to expand its Open Access Publishing through its 50+ journals in association with 20+ International medical and scientific societies.
Pulsus through its pulsusconference.com is been very instrumental to provide an invaluable channel for scientists and researchers to exchange ideas and research by creating a forum for discussing the possibilities of future collaborations between universities, institutions, research bodies and organizations from different countries through international CME/CPD accredited conferences and meetings.
Why to attend?
Alzheimers 2018 is an ideal opportunity to create awareness about the leading advancements in the therapies for the cure of Alzheimer's, Dementia and many other neurodegenerative diseases and the direction of future developments. This Conference will be an exciting opportunity to share academic and clinical developments and research and to build on social interactions and support each other.
The main aim of our conference is to gather individuals from Neurology and to share their ideas and inventions for the well being of mankind.
Benefits
Who should attend?
Target Audience
Session 1: Dementia
Dementia is a common term to describe memory loss leading to hindrance in daily routines. It is specifically not a single disease, it describes many symptoms associated with the brain's working capacity. Alzheimer's is the most common type of Dementia. Vascular dementia which is the second most common type is caused after stroke in brain cells. People with dementia faces many difficulties in communicating with others, memorizing things, ability to focus and pay attention, judgment and reasoning, visual perception.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Session 2: Alzheimer and Parkinson
Alzheimer's Disease (AD) affects the proper memory power, thinking ability and brings behavioral change in a human being. AD is not a normal part of aging, it gets worse with increasing age. Currently, no proper medicine is available to cure AD, researchers are working on it to find out medications for proper cure. Parkinson Disease (PD) affects the predominately dopamine producing neurons in particular area of brain known as substantia nigra. It causes tremors in body, slowness of movements, rigidity of limb, gait and balance problems. Some societies provides assisted living facilities for patients with AD and PD. The patients can’t take decisions on their own, so they assign someone for all legal works which includes creating power of attorney also.
Related Conferences:
World Congress on Neurology and Therapeutics, February 28-March 02, 2019, Berlin, Germany; Annual Congress on Neurology & Neuroscience, March 14-15, 2019, Paris, France; International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland; Israel Society for Neuroscience Meeting 2019, January 6-8, 2019, Eilat, Israel; Biannual Meeting of the Hungarian Neuroscience Society, January 17-18, 2019, Hungary; Gottigen Meeting of the German Neuroscience Society, March 20-23, 2019, Göttingen, Germany; International Conference on Alzheimer's and Parkinson's Diseases, March 26-31, 2019, Lisbon, Portugal.
Related Societies and Associations:
Alzheimer Europe, Alzheimer Society Toronto, Parkinson's Foundation, Parkinson's Disease And Movement Disorder Society, Neurodegenerative Disease Society of Toronto - NDST, Dementia Action Alliance, The Alzheimer's Society of Ireland, Neuroscience Society.
Session 3: Epilepsy
Epilepsy is a neurological disorder in which the nerve cells activities is disrupted leading to seizures. The ability to interpret feelings slows down which is known as aura. The person becomes apathic in nature. After a seizure takes place, it leaves the body in postictal state. The brain’s electrical activity is recorded by Electroencephalogram to do the monitoring and to find out the affected part. Anticonvulsants and proper diet are given to minimize the effects of epilepsy. All over world, approximately 50 million people are dealing with epilepsy.
Related Conferences:
International Conference on Dementia and Alzheimers Disease, March 25-26, 2019, Osaka, Japan; World Congress on Alzheimers Disease & Dementia, March 20-21, 2019, Sydney, Australia; Global Experts Meeting on Parkinsons, Huntingtons & Movement Disorders, May 08-09, 2019, Tokyo, Japan; Annual Update Conference on Neurology and Neurophysiology, February 18-19, 2019, Tel Aviv, Israel; International Conference on Alzheimer’s Disease & Dementia, May 20 - 22, 2019, Osaka, Japan; European Stroke Organisation Conference, May 22-24, 2019, Milan, Italy; Annual Meeting of the Japanese Society of Neuroscience, May 22-25, 2019, Osaka, Japan.
Related Societies and Associations:
Pilgrims' Friendly Society, The Dementia Society Ottawa and Renfrew Country, Alzheimer Society of Calgary, Parkinson's UK, Epilepsy Foundation, Parkinson Canada, American Epilepsy Society, International Behavioural Neuroscience Society.
Session 4: Multiple Sclerosis
An uncertain disease of Central Nervous System (CNS) in which the protecting covers of nerve cells of spinal cord and brain are deteriorated. Many investigators thinks MS to be a autoimmune disorder in which the immune system of body launches a defensive mechanism for its safety. There is no specific cure for Multiple Sclerosis (MS), many patients do well with therapies, because medications have may side effects. A patient with MS faces difficulties in communicating with others. New research are being done to work with stem cells for treatment of MS. Genetics play a major role in getting affected by MS, Vitamin D plays a role in treatment but still its proper use is not specified, to stop the spread of MS we need to find treatment for repairing of myelin sheath.
Related Conferences:
International Conference on Brain Injury and Neuroscience, March 14-15, 2019, Paris, France; 5th International Conference on Neurological Disorders & Stroke, May 20-21, 2019, Osaka, Japan; World Congress on Advances in Brain Injury, Disorders and Therapeutics, October 21-22, 2019, Tokyo, Japan; International Neuropsychological Society (INS) 47th Annual Meeting, February 20-23, 2019, New York, USA; International Brain Stimulation Conference, February 24-27, 2019, Vancouver, British Columbia; World Congress on Brain Injury, Mar 13-16, 2019, Toronto, Ontario; Congress of the International Headache Society (IHC), September 06-09, 2019, Dublin, Leinster.
Related Societies and Associations:
The ALS Association, Alzheimer's Research UK (ARUK), Fisher Center for Alzheimer's Research Foundation, Neurological Society of India, World Federation of Neurology, European Federation of Neurological Associations, British Neuroscience Association, Society of Neuroscience.
Session 5: Migraine
Migraine headache results from any physiological changes in brain resulting in nausea and vomiting. Pain is very intense and unbearable after some extent which may get worse after physical extortion. Usually it affects only one side of brain but in few cases it affects bilaterally. In some cases, people experiences warning symptoms or an aura which ranges from flashing lights, loud music and blind spots. Factors which trigger migraine are hormonal imbalances, oral contraceptive pills, certain food products, stress, oversleeping, etc. Diclofenac is a easily available medicine for relief of migraine pain. Proper diet and exercise should be maintained to get relief.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Session 6: Prion Disease
Transmissible spongiform encephalopathies (TSEs), generally known as prion diseases are a cluster of degenerative brain disorders defined by tiny holes giving a spongy appearance to the brain. Prions are infectious agents composed entirely of proteins. This can be diagnosed when brain tissue is diagnosed under microscope. Very rare disorder, which affects one in every one million people every year. TSEs progress rate is very high which usually results in death. Proper treatment is not available till now, research is being going on to find out cure for TSEs.
Related Conferences:
World Congress on Neurology and Therapeutics, February 28-March 02, 2019, Berlin, Germany; Annual Congress on Neurology & Neuroscience, March 14-15, 2019, Paris, France; International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland; Israel Society for Neuroscience Meeting 2019, January 6-8, 2019, Eilat, Israel; Biannual Meeting of the Hungarian Neuroscience Society, January 17-18, 2019, Hungary; Gottigen Meeting of the German Neuroscience Society, March 20-23, 2019, Göttingen, Germany; International Conference on Alzheimer's and Parkinson's Diseases, March 26-31, 2019, Lisbon, Portugal.
Related Societies and Associations:
Alzheimer Europe, Alzheimer Society Toronto, Parkinson's Foundation, Parkinson's Disease And Movement Disorder Society, Neurodegenerative Disease Society of Toronto - NDST, Dementia Action Alliance, The Alzheimer's Society of Ireland, Neuroscience Society.
Session 7: Motor Neurone Diseases
Motor Neurone Diseases are a collection of conditions which cause the nerves in brain and spine to stop its function. They are rare but fatal and incurable form of neurodegeneration. It can decrease the life expectancy of an individual. Motor neuron diseases affect either upper motor neurons (UMN) or lower motor neurons (LMN). It is a more likely to be a genetic disorder but doesn’t runs in many generations. Physiotherapy and speech and language therapist can help in living healthy life. Only few drugs are available to slightly slow down the progress of this condition, no proper treatment is available. The patients becomes emotionally very weak, so proper care and love should be shown. Few people who are dealing with ALS which is a type of Motor Neurone Disease are Stephen Hawking and Jason Becker have been living for several years.
Related Conferences:
International Conference on Dementia and Alzheimers Disease, March 25-26, 2019, Osaka, Japan; World Congress on Alzheimers Disease & Dementia, March 20-21, 2019, Sydney, Australia; Global Experts Meeting on Parkinsons, Huntingtons & Movement Disorders, May 08-09, 2019, Tokyo, Japan; Annual Update Conference on Neurology and Neurophysiology, February 18-19, 2019, Tel Aviv, Israel; International Conference on Alzheimer’s Disease & Dementia, May 20 - 22, 2019, Osaka, Japan; European Stroke Organisation Conference, May 22-24, 2019, Milan, Italy; Annual Meeting of the Japanese Society of Neuroscience, May 22-25, 2019, Osaka, Japan.
Related Societies and Associations:
Pilgrims' Friendly Society, The Dementia Society Ottawa and Renfrew Country, Alzheimer Society of Calgary, Parkinson's UK, Epilepsy Foundation, Parkinson Canada, American Epilepsy Society, International Behavioural Neuroscience Society.
Session 8: Huntingtons Disease
It is a progressive type of dementia which is caused by mutation in gene for protein called huntingtin. It affects the central part of the brain resulting in defects in movement, moods and thinking skills. There is no cure which can block or reverse the course of Huntingtons Disease. Every child of parent with HD gene has 50/50 chance of inheriting the gene causing disease. If the child have not inherited gene, he or she will never show any symptom and it will not pass on to their next generation. Antipsychotic drugs are there for temporary relief but it comes up with side effects like cholera, nausea, fatigue, etc. HD causes disability which worsens with time. People with this gene mutation usually dies within 15-20 years after getting diagnosed.
Related Conferences:
International Conference on Brain Injury and Neuroscience, March 14-15, 2019, Paris, France; 5th International Conference on Neurological Disorders & Stroke, May 20-21, 2019, Osaka, Japan; World Congress on Advances in Brain Injury, Disorders and Therapeutics, October 21-22, 2019, Tokyo, Japan; International Neuropsychological Society (INS) 47th Annual Meeting, February 20-23, 2019, New York, USA; International Brain Stimulation Conference, February 24-27, 2019, Vancouver, British Columbia; World Congress on Brain Injury, Mar 13-16, 2019, Toronto, Ontario; Congress of the International Headache Society (IHC), September 06-09, 2019, Dublin, Leinster.
Related Societies and Associations:
The ALS Association, Alzheimer's Research UK (ARUK), Fisher Center for Alzheimer's Research Foundation, Neurological Society of India, World Federation of Neurology, European Federation of Neurological Associations, British Neuroscience Association, Society of Neuroscience.
Session 9: Spinocerebellar Ataxia
Spinocerebellar ataxia (SCA) is gradually developing degeneration of nerves, which is a genetic disease having numerous other types. Also known as Sprinocerebellar atrophy or spinocerebellar degeneration. There is no proper cure or treatment, so, sometimes it becomes fatal. It can affect person of any age group generally 1 or 2 in 1 million people worldwide. This condition is inherited in autosomal dominant nature, which states that only one copy of altered gene is enough to cause the disorder. Only rehabilitation can help patients to deal with SCA.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Session 10: Spinal Muscular Atrophy
Spinal Muscular Atrophy is a hereditary disease which cause weakness and wastage in the voluntary muscles of legs and arms of infants and children. This disorder is caused by an abnormal or missing gene known as survival motor neuron gene. There are 3 types of SMA; Type 1 is evident at birth or in first few weeks, Type 2 normally begins in 6 to 18 months and Type 3 usually shows in between 2 and 17 years of age. There is no cure of SMA, treatment mainly consists of management of symptoms and prevention of complications. Researchers have started doing work in the field of strategies to cope up with SMA. The US FDA have approved nusinersen (brand name Spinzara) to carry out treatment of SMA on Dec. 23, 2016.
Related Conferences:
World Congress on Neurology and Therapeutics, February 28-March 02, 2019, Berlin, Germany; Annual Congress on Neurology & Neuroscience, March 14-15, 2019, Paris, France; International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland; Israel Society for Neuroscience Meeting 2019, January 6-8, 2019, Eilat, Israel; Biannual Meeting of the Hungarian Neuroscience Society, January 17-18, 2019, Hungary; Gottigen Meeting of the German Neuroscience Society, March 20-23, 2019, Göttingen, Germany; International Conference on Alzheimer's and Parkinson's Diseases, March 26-31, 2019, Lisbon, Portugal.
Related Societies and Associations:
Alzheimer Europe, Alzheimer Society Toronto, Parkinson's Foundation, Parkinson's Disease And Movement Disorder Society, Neurodegenerative Disease Society of Toronto - NDST, Dementia Action Alliance, The Alzheimer's Society of Ireland, Neuroscience Society.
Session 11: Demyelinating Diseases
It is a condition in which the myelin sheath of nerve fibres of brain, optic nerves and spinal cord are damaged. When myelin sheath gets deteriorated, nerve impulses slows down or often stops working causing many neurological problems. Demyelination tends to be patchy or segmental, affecting multiple areas simultaneously. Remyelination often takes place with complete recovery and regeneration of nerve cells. Demyelination is caused by viral infections, metabolic issues, oxygen loss and physical compression. Symptoms include numbness, loss of reflex actions, blurred vision, memory loss, fatigue, etc. There are vaccines to help decrease chances of demyelination. They are not curable but taking with your doctor helps in better understanding of the problem.
Related Conferences:
International Conference on Dementia and Alzheimers Disease, March 25-26, 2019, Osaka, Japan; World Congress on Alzheimers Disease & Dementia, March 20-21, 2019, Sydney, Australia; Global Experts Meeting on Parkinsons, Huntingtons & Movement Disorders, May 08-09, 2019, Tokyo, Japan; Annual Update Conference on Neurology and Neurophysiology, February 18-19, 2019, Tel Aviv, Israel; International Conference on Alzheimer’s Disease & Dementia, May 20 - 22, 2019, Osaka, Japan; European Stroke Organisation Conference, May 22-24, 2019, Milan, Italy; Annual Meeting of the Japanese Society of Neuroscience, May 22-25, 2019, Osaka, Japan.
Related Societies and Associations:
Pilgrims' Friendly Society, The Dementia Society Ottawa and Renfrew Country, Alzheimer Society of Calgary, Parkinson's UK, Epilepsy Foundation, Parkinson Canada, American Epilepsy Society, International Behavioural Neuroscience Society.
Session 12: Cerebral Palsy
Cerebral Palsy is a group of neurological disorders which appears in infants or early childhood causing permanent affect in body movements, muscle coordination and balance. Early signs usually appears before 3 years of age, if not visible in infant stage. Symptoms includes reflex actions, seizures, hearing loss and impaired or blurred vision. It is not a progressive disease, which means it doesn’t worsens with time. It is not totally curable but with proper care, a child’s capabilities can be checked. Treatment may include therapies, surgery to correct anatomical abnormalities. CP occurs in about 2.1 per 1000 live births. With proper care and treatment, children with CP can live normally like others.
Related Conferences:
International Conference on Brain Injury and Neuroscience, March 14-15, 2019, Paris, France; 5th International Conference on Neurological Disorders & Stroke, May 20-21, 2019, Osaka, Japan; World Congress on Advances in Brain Injury, Disorders and Therapeutics, October 21-22, 2019, Tokyo, Japan; International Neuropsychological Society (INS) 47th Annual Meeting, February 20-23, 2019, New York, USA; International Brain Stimulation Conference, February 24-27, 2019, Vancouver, British Columbia; World Congress on Brain Injury, Mar 13-16, 2019, Toronto, Ontario; Congress of the International Headache Society (IHC), September 06-09, 2019, Dublin, Leinster.
Related Societies and Associations:
The ALS Association, Alzheimer's Research UK (ARUK), Fisher Center for Alzheimer's Research Foundation, Neurological Society of India, World Federation of Neurology, European Federation of Neurological Associations, British Neuroscience Association, Society of Neuroscience.
Session 13: Cognitive Impairment
Mild cognitive impairment causes mild but noticeable changes in decrease of cognitive abilities like thinking abilities and memory power. It is an intermediate stage between cognitive decline of normal aging and the severe signs of dementia. In amnestic MCI, person starts to forget important information's like appointments, conversations, etc. Whereas in nonamnestic MCI, person’s thinking ablility is hampered. There is no cause for MCI, but studies shows that shrinkage of hippocampus, enlargement of brain’s fluid-filled spaces and reduced use of glucose may be possible causes. Risk factors for MCI- increasing age, lifestyle problems and a presence of a specific form of gene APOE-e4, though presence of this gene doesn’t assure that an individual can get MCI. The prevalence of MCI varies by age group. 6.7% for ages 60–64; 8.4% for ages 65–69, 10.1% for ages 70–74, 14.8% for ages 75–79, and 25.2% for ages 80–84. No medications are there to treat MCI properly.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Session 14: Stroke
Brain attack or stroke takes place when circulation of blood in brain is interrupted or the blood vessels bursts and squirts out blood. The brain cells die due to reduced oxygen flow and functioning of brain stops. Stroke has no defined symptoms, all will take place suddenly and after affects will be there. The treatment stages are prevention, therapy after the brain attack and post stroke rehabilitation. Most popular class of drug to treat strokes are antithrombotics (antiplatelet agents and anticoagulants) and thrombolytics. The most disability which takes place after stroke is one-sided paralysis. Clinical trails have been done by Worldwide Scientists to know about stroke. Many organizations help patients with stroke to live life to the fullest.
Related Conferences:
World Congress on Neurology and Therapeutics, February 28-March 02, 2019, Berlin, Germany; Annual Congress on Neurology & Neuroscience, March 14-15, 2019, Paris, France; International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland; Israel Society for Neuroscience Meeting 2019, January 6-8, 2019, Eilat, Israel; Biannual Meeting of the Hungarian Neuroscience Society, January 17-18, 2019, Hungary; Gottigen Meeting of the German Neuroscience Society, March 20-23, 2019, Göttingen, Germany; International Conference on Alzheimer's and Parkinson's Diseases, March 26-31, 2019, Lisbon, Portugal.
Related Societies and Associations:
Alzheimer Europe, Alzheimer Society Toronto, Parkinson's Foundation, Parkinson's Disease And Movement Disorder Society, Neurodegenerative Disease Society of Toronto - NDST, Dementia Action Alliance, The Alzheimer's Society of Ireland, Neuroscience Society.
Session 15: Convulsion
Convulsion is a state in which the whole body muscle contracts and relaxes very quickly resulting in uncontrolled shaking of body. Convulsion is also used as a term for seizures. This takes place due to some sort of electrical activity mishap in brain. Also it can be caused by chemicals in blood or some infections like meningitis. Symptoms usually last from few seconds to around 20 minutes.
Related Conferences:
International Conference on Dementia and Alzheimers Disease, March 25-26, 2019, Osaka, Japan; World Congress on Alzheimers Disease & Dementia, March 20-21, 2019, Sydney, Australia; Global Experts Meeting on Parkinsons, Huntingtons & Movement Disorders, May 08-09, 2019, Tokyo, Japan; Annual Update Conference on Neurology and Neurophysiology, February 18-19, 2019, Tel Aviv, Israel; International Conference on Alzheimer’s Disease & Dementia, May 20 - 22, 2019, Osaka, Japan; European Stroke Organisation Conference, May 22-24, 2019, Milan, Italy; Annual Meeting of the Japanese Society of Neuroscience, May 22-25, 2019, Osaka, Japan.
Related Societies and Associations:
Pilgrims' Friendly Society, The Dementia Society Ottawa and Renfrew Country, Alzheimer Society of Calgary, Parkinson's UK, Epilepsy Foundation, Parkinson Canada, American Epilepsy Society, International Behavioural Neuroscience Society.
Session 16: Neurodegeneration
Neurodegeneration is a progressive loss of neuron’s structure and function leading towards an irreversible damage and death of neurons. It is final stage for aging and a pathway for neurodenegerative diseases. It encircles a wide range of clinical diseases like Alzheimer’s Disease, Parkinson’s Disease and many other neurological disorders. Degenerative diseases may be life threatening or non-curable. Treatments and therapies may improve symptoms, relieve pains and will also help in increasing mobility. These problems gets diagnosed by ECG and some specific nerve tests.
Related Conferences:
International Conference on Brain Injury and Neuroscience, March 14-15, 2019, Paris, France; 5th International Conference on Neurological Disorders & Stroke, May 20-21, 2019, Osaka, Japan; World Congress on Advances in Brain Injury, Disorders and Therapeutics, October 21-22, 2019, Tokyo, Japan; International Neuropsychological Society (INS) 47th Annual Meeting, February 20-23, 2019, New York, USA; International Brain Stimulation Conference, February 24-27, 2019, Vancouver, British Columbia; World Congress on Brain Injury, Mar 13-16, 2019, Toronto, Ontario; Congress of the International Headache Society (IHC), September 06-09, 2019, Dublin, Leinster.
Related Societies and Associations:
The ALS Association, Alzheimer's Research UK (ARUK), Fisher Center for Alzheimer's Research Foundation, Neurological Society of India, World Federation of Neurology, European Federation of Neurological Associations, British Neuroscience Association, Society of Neuroscience.
Session 17: Neurorehabilitation
Neurorehabilitation is a treatment of nerves affected by neurodegenerative disorders specially designed and supervised by doctors. It often improves function, reduces symptoms which affects the overall condition of patients to some extent. Many experts from different fields have to come together as a team to make it a success like neurosurgeon, orthopedic surgeon therapist, counselor, social workers, psychiatrist. It takes into account diseases such as Dementia, Alzheimer’s, Parkinson’s, etc. This treatment promotes the highest level of independence possible for them. It also helps in rebuilding self-esteem and a positive attitude towards the life which results in getting adapted to new situations. It gives a ray of hope to the patients. All over the world, there are many cases of patients who have got relief from many serious neurological diseases by this neurorehabilitation technique.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Session 18: Neurology
Neurology is a special branch of medical sciences which deals primarily with disorders in the nervous system. It involves diagnosing and treating conditions related to the central, peripheral and autonomic nervous system. The person who deals with this branch is called as Neurologist. In this branch, the root cause of problem is identified and then proper therapies and treatments are provided to get rid if the problem. Neuroscience describes the scientific study of the mechanics of the central nervous system such as its function, genetics and physiology, structure as well as its application to understand diseases of the nervous system.
Related Conferences:
World Congress on Neurology and Therapeutics, February 28-March 02, 2019, Berlin, Germany; Annual Congress on Neurology & Neuroscience, March 14-15, 2019, Paris, France; International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland; Israel Society for Neuroscience Meeting 2019, January 6-8, 2019, Eilat, Israel; Biannual Meeting of the Hungarian Neuroscience Society, January 17-18, 2019, Hungary; Gottigen Meeting of the German Neuroscience Society, March 20-23, 2019, Göttingen, Germany; International Conference on Alzheimer's and Parkinson's Diseases, March 26-31, 2019, Lisbon, Portugal.
Related Societies and Associations:
Alzheimer Europe, Alzheimer Society Toronto, Parkinson's Foundation, Parkinson's Disease And Movement Disorder Society, Neurodegenerative Disease Society of Toronto - NDST, Dementia Action Alliance, The Alzheimer's Society of Ireland, Neuroscience Society.
Session 19: Neuropathy
Neuropathy refers to a condition in which the whole nervous system is affected. It may lead to some neurodegenerative diseases. It’s symptoms include numbness or tingling, to pricking sensations in legs or arms, muscle weakness. Neuropathy affecting just one nerve is known as mononeuropathy whereas if its effect is shown in many nerve cells then it is called as symmetrical polyneuropathy or simply neuropathy. It is caused by genetic diseases, endocrine and metabolic diseases, inflammatory disease, etc. Many medications have been found which eases the neuropathic pain.
Related Conferences:
International Conference on Dementia and Alzheimers Disease, March 25-26, 2019, Osaka, Japan; World Congress on Alzheimers Disease & Dementia, March 20-21, 2019, Sydney, Australia; Global Experts Meeting on Parkinsons, Huntingtons & Movement Disorders, May 08-09, 2019, Tokyo, Japan; Annual Update Conference on Neurology and Neurophysiology, February 18-19, 2019, Tel Aviv, Israel; International Conference on Alzheimer’s Disease & Dementia, May 20 - 22, 2019, Osaka, Japan; European Stroke Organisation Conference, May 22-24, 2019, Milan, Italy; Annual Meeting of the Japanese Society of Neuroscience, May 22-25, 2019, Osaka, Japan.
Related Societies and Associations:
Pilgrims' Friendly Society, The Dementia Society Ottawa and Renfrew Country, Alzheimer Society of Calgary, Parkinson's UK, Epilepsy Foundation, Parkinson Canada, American Epilepsy Society, International Behavioural Neuroscience Society.
Session 20: Headache
Headache is immense pain anywhere in the head and neck. It occurs during migraine, tension-type headaches and cluster headaches. There is risk of depression in some cases of severe headache. Causes may include stress, fatigue, sleep deprivation, effects of medication, loud noises, viral infections, head injury, etc. Migraine is a common type of headache. Treatment includes underlying pain, but majorly involves medication.
Related Conferences:
International Conference on Brain Injury and Neuroscience, March 14-15, 2019, Paris, France; 5th International Conference on Neurological Disorders & Stroke, May 20-21, 2019, Osaka, Japan; World Congress on Advances in Brain Injury, Disorders and Therapeutics, October 21-22, 2019, Tokyo, Japan; International Neuropsychological Society (INS) 47th Annual Meeting, February 20-23, 2019, New York, USA; International Brain Stimulation Conference, February 24-27, 2019, Vancouver, British Columbia; World Congress on Brain Injury, Mar 13-16, 2019, Toronto, Ontario; Congress of the International Headache Society (IHC), September 06-09, 2019, Dublin, Leinster.
Related Societies and Associations:
The ALS Association, Alzheimer's Research UK (ARUK), Fisher Center for Alzheimer's Research Foundation, Neurological Society of India, World Federation of Neurology, European Federation of Neurological Associations, British Neuroscience Association, Society of Neuroscience.
Session 21: Neurologist
A neurologist is a expert in neurology and is trained in diagnosing, investigating and treating neurological disorders. They are involved in clinical trials, clinical research and translational or basic research. During treatment, first they will do perform a physical exam and then a neurological exam. A neurologist may serve as consultant to other physicians or they can provide long-term treatment to a patient having neurological disorders. Treatment includes medication, therapies and in severe cases surgery.
Related Conferences:
World Brain Congress, December 5-7, 2018, Dubai, UAE; Annual Conference on Dementia and Alzheimers Disease, December 13-15, 2018, Abu Dhabi, UAE; International Conference on Vascular Dementia, February 15-16, 2019, Amsterdam, Netherlands; Winter Conference on Brain Research, January 28-February 2, 2019, Snowmass, Colorado; World Parkinson Congress, June 4-7, 2019, Kyoto, Japan; ISN-ASN Meeting, August 04-08, 2019, Montréal, Canada; World Congress of Neurology (WCN 2019), October 26-31, 2019, Dubai, United Arab Emirates.
Related Societies and Associations:
Dementia Society of America, Alzheimer's Association, Alzheimer's Society United Against Dementia, Dementia UK, Alzheimer Society Canada, Alzheimer Society Ontario, Alzheimer's & Related Disorders Society of India, Cognitive Neuroscience Society.
Importance and Scope:
The main objective of Alzheimers 2018 Conference is to know more about the neurodegenerative diseases and to create awareness for the same. This conference will try to understand the concerns leading to Alzheimer’s disease, Parkinson’s disease, Dementia and many other neurodegenerative diseases. It will also help the mankind to know more about the techniques and therapies to live life positively and to become a better individual.
About Venue:
Madrid, the capital city of Spain is one of the liveliest city where the energy of the city carries a message: the city really knows how to live and enjoy every moment. Madrid is an open-minded city where entertainment and culture shares a space which basically comes from the modern and cosmopolitan folks and to the passionate and friendly character of citizens of Madrid. It is regarded as a very popular holiday destination for summer vacations. It is one of most popular tourist attractions site. Madrid offers its visitors a very incomparable tour of the city in which few places are Buen Retiro Park, Plaza Mayor, Museo Nacional Del Prado, Royal Palace of Madrid, Temple of Debod, Puerta de Alcala, The Madrid Zoo Aquarium, Las Ventas. Persons having interest in history must visit this place to increase their knowledge.
Why Alzheimers 2018 will be in Spain?
More than 800,000 people are dealing with Alzheimer’s or any other form of Neurodegenerative disorders in Spain, globally which is 46.8 million. This conference will help the citizens of Spain to know more about the leading advancements in therapies and treatments for the same. Many societies and associations are working to create awareness and to provide care to the patients of dementia. The death rate is increasing without proper knowledge. Madrid, Spain will be a perfect host for the conference which will be suitable to create awareness and to spread the message globally.
Alzheimers, Dementia and Other Neurodegenerative Diseases- Globally
Worldwide over 46.8 million people have Alzheimer’s disease or a related dementia in 2015 which is increased to near about 50 million in 2017 which is more than the total population of Spain and it is estimated to increase to 131.5 by 2050. Only 1 in 4 has been diagnosed. These problems are most common in Western Europe. Around 134 universities and 97 societies are working in the research to create awareness about Alzheimer’s and other neurodegenerative diseases and paving a way to deal with the diseases. Dementia also has a huge economic impact. In World Alzheimer Report, it was stated that the estimated global cost of dementia is US $818 billion, which may become a trillion dollar disease by 2018. This states the if dementia care were a country, it would be the world’s 18th largest economy which is more than many market values of big companies like Google, Apple, etc.
In 2016, The World Health Organisation (WHO) established a Global Dementia Observatory (GDO) to give data, analyses and global highlight of dementia. In many parts of the world, the awareness about dementia is growing, but across the globe it remains the same case that diagnosis of dementia will bring stigma to society which will result in social isolation. 58% of people having dementia are in low and middle income countries. Today 95% of people dealing with dementia of middle and low income countries are taken care at home. These regions often provide low or limited support to the person having dementia or to their families. Seeing the epidemic scale of dementia, with no cure and globally increasing population, we are calling on every block of society to play an active role in helping to create awareness about the diseases and to make a world better place to live.
Global Business & Research Value
Dementia, Alzheimers and other Neurodegenerative diseases have a very significant social and economic implementation in terms of direct medical costs, social costs and costs for informal care.
The costs of Dementia Care globally were estimated at United States (US) $818 billion in 2015, which is higher by 35% since 2010. The costs of informal care and the direct costs of social care still contribute similar proportions of the total costs, whereas medical sector costs is much lower. The threshold of US $1 trillion will be crossed by 2018.
The cost of dementia care to the UK is now £26 billion a year, which works out as an average annual cost of £32,250 per person with dementia. Two-thirds of this cost is being paid by people with dementia and their families, rest is either in unpaid care (£11.6 billion) or in paying for private social care.
Only about one third of the total population suffering from neurodegenerative disorders are getting therapies and medicines and getting benefitted by it. Mental illnesses are causing a very huge burden for social and economic aspect of society. It is found that the cost burden of these and other neurological disorders amounted to about 652 billion euros ($800 billion) a year. Deaths by Dementia, Alzheimer’s, Parkinson’s, Epilepsy, Stroke has increased by 36.7% Worldwide. An estimated 6.9 million people die every year as a result of neurological disorders.
Allergan, Eisai, Novartis, and Teva Pharmaceutical Industries are the key vendors in the global dementia treatment market.
This industry research report also presents a competitive analysis of the market by drug class (MAO inhibitors, AChE inhibitors, and Glutamate inhibitors) and by geography (the Americas, APAC, and EMEA).
Market research analysts at Technavio predict that the global dementia and movement disorder treatment market will grow at a CAGR of more than 4% by 2021. This market research analysis identifies the need for disease modifying drugs (DMDs) as one of the primary growth factors for this market.
Alzheimers, Dementia and Other Neurodegenerative Diseases in Europe
Alzheimer’s, Parkinson’s and Dementia are the greatest contributors to increasing death rate in Europe. Alzheimers's Disease is diagnosed in people over 65 years of age, while it can also occur in younger people also. Around 7.5 million cases of dementia are recorded in Europe. The number of people dealing with dementia may increase from 7.5m in 2015 to 14.3m in 2050. Rates of women suffering from Alzheimer’s are more than men (Men- 3.31%, women-7.13%). Over 5.2% of people over the age group of 60 are dealing with dementia globally. High income population have more chances of getting dementia rather than the low income population.
Societies working for Alzheimer’s disease in Europe:
Universities in Europe working for Alzheimer’s disease
Around 500 top universities globally working in the field of Neuroscience
There are around 200 universities in Spain which are working in the field of Neurology
There are about 15 Universities in and around Madrid which are working in the field of Neurology
Hospitals Associated with Neuroscience Research
All around the globe there are 6000 hospitals working on Neurology
Some of them among them are:
There are around 120 hospitals in Spain exclusively working on Neurology
Companies associated with Neurological Disorders Research